|Bid||4.6000 x 1200|
|Ask||7.5000 x 900|
|Day's Range||4.8100 - 5.0550|
|52 Week Range||4.2000 - 16.2300|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
So far this earnings season, the going seems to be good for the medical sector. Let us take a glance at a few small drug companies, which are likely to beat on Q1 earnings.
Alibaba's (BABA) fourth-quarter fiscal 2019 results are likely to be driven by strength in core e-commerce business. However, trade tensions and competition remain concerns.
Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).
TripAdvisor's (TRIP) first-quarter results are likely to benefit from strong product portfolio and strength in non-hotel business.
Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.
If you want to know who really controls Neon Therapeutics, Inc. (NASDAQ:NTGN), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...
Neon Therapeutics Inc (NASDAQ: NTGN ) develops vaccine based on neoantigens — markers unique to each individual tumor — to improve tumor response in checkpoint inhibitors such as Merck & Co., Inc. (NYSE: ...